Authors
Latest:
Shared Understanding Creates CultureWhile culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.
Latest:
Compliance as Usual Doesn’t Cut it AnymoreHow pharma companies can bolster their quality management programs to meet FDA’s evolving compliance requirements.
Latest:
Translation Automation: A Viable Solution?Global content management needs are mounting among life sciences organizations, as they expand their market coverage and grapple with multiplying regulatory workloads. Monica Vytiskova asks if can intelligent automation offer a solution.
Latest:
Keeping Up with Telehealth: Pharma’s EvolutionIf telehealth is here to stay, how is the industry adjusting?
Latest:
How to Harness, Leverage Key Online InfluencersThe importance of KOIs in tapping into today’s market mindset.
Latest:
How to Harness, Leverage Key Online InfluencersThe importance of KOIs in tapping into today’s market mindset.
Latest:
CEOs Sound Out on Health Reform: Stop Swinging from the FenceAt last week’s 4th annual Prix Galien Forum hosted by the Alexandria Center in New York, industry leaders gathered to discuss trends and developments that shape the intersection between science and policy.
Latest:
Restoring Pharma's ReputationA 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".
Latest:
Policy Sync-Up: The Drug Importation ConundrumCoexisting with the DSCSA may hinder new legislative efforts.
Latest:
High-Stakes Manufacturing: Mitigating the RisksHow to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
Latest:
High-Stakes Manufacturing: Mitigating the RisksHow to navigate the production and reimbursement intricacies of bringing regenerative medicines from bench to bedside.
Latest:
Four Takeaways from the Zolgensma Pricing StormFour takeaway messages from the Zolgensma pricing storm
Latest:
Routes to Exclusivity in Cell-Based Therapy DevelopmentOutlining the critical steps for companies in controlling market exclusivity for their gene therapies.
Latest:
Routes to Exclusivity in Cell-Based Therapy DevelopmentOutlining the critical steps for companies in controlling market exclusivity for their gene therapies.
Latest:
Are Outcomes-Based Deals Only a Band-Aid for High Drug Prices?Outcomes-based contracts seem to have the potential to make drugs more affordable, but not without mutually-beneficial, data-driven arrangements.
Latest:
Pharma Automation: Avoiding the DangersThe key steps to evading automation-fueled data crises.
Latest:
Career Paths and Title Inflation in the Pharmaceutical IndustryDo’s and Dont’s while facing the increased war for talent.
Latest:
Gene Therapy: The Road to IndustrializationClive Glover and Mark Szczypka discuss the complexities of scaling up the manufacturing of gene therapies and gene-modified cell therapies to industrial levels.
Latest:
Building Healthcare Organizations That Put People FirstEvery healthcare company should be striving to identify better ways to ensure patients and consumers inspire every decision they make, writes Joanne Waldstreicher.
Latest:
A Bold Deal Could Help Trump Administration End HIV in AmericaThe US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.
Latest:
Liberating Patient DataAiden Flynn discusses mining real-world data pools to transform drug development.
Latest:
Medical Devices' Big Regulatory Shake-Up: What Now?Ben Jacoby assesses the scope for disruption of the significant changes in medical device transparency and traceability requirements, and advises on a practical response.
Latest:
Shifting Patent Litigation Trends Favor Branded Pharma CompaniesThe latest trends in patent litigation has led to a more harmonized patent system, which can benefit pharmaceutical companies that invest in patents.
Latest:
The Synergistic OrganizationA key question for an organization post-M&A is: “What organizational capabilities support global guidance and leadership, and which of them require these at the 'local' level?” Scott Hull discusses potential solutions.
Latest:
A Blueprint for BalanceStephen Rivera, vice president, global technical accounting advisory services and policy, Johnson & Johnson, capitalizes on his lively personality—and a courageous career journey—to bring people together to shape the future of biopharma.
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
Latest:
Attacks on Pharmaceutical Improvement PatentsIs Congress harming pharmaceutical research by limiting enforcement of improvement patents?
